EasyBlog

This is some blog description about this site

UNION therapeutics A/S (UNION) today announced that it has entered into a strategic veterinary partnership with Ceva Santé Animale S.A. (Ceva) on the candidate UNI836.

Under the agreement, Ceva will be developing UNI836 for treatment of canine pyoderma. Canine pyoderma is one of the most frequent diseases in companion animals and a significant burden for both animal patients and their owners.

Chief Executive Officer of UNION, Dr. Rasmus Toft-Kehler, commented: “We appreciate to be collaborating with one of the fastest growing veterinary care companies on broadening the utility of the compound class. The results generated in collaboration with Ceva indicates that UNI836 has the potential to become a new and highly innovative treatment for companion animals and their owners”. Dr. Morten Sommer, Chief Scientific Officer of UNION, further commented: “Our collaborative efforts have highlighted the novel mechanism of action underlying UNI836 to provide an interesting approach to tackle an unmet medical need in the veterinary space. We look forward to continue working with Ceva on the advancement of UNI836 for treatment of canine pyoderma”.

Dr. Pascal Anjot, VP Global R&D & Innovation, Ceva added: "We are very pleased to be associated with UNION therapeutics for the development of this new opportunity in the treatment of Pyoderma in companion animals. Ceva has long been at the forefront of promoting the rational use of antibiotics in veterinary medicine. The GRAM (Guidance for the Rational use of Antimicrobials) initiative developed together with leading European experts is a good example and this new project with UNION offers to provide veterinarians with a very innovative, therapeutic approach to the treatment of this condition, in line with this aim of continually developing best practice".

As part of the agreement, Ceva will be taking responsibility for further development and global commercialization of UNI836.

About UNION:
UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. The leadership team of UNION has invented and successfully developed more than 10 approved human medicines. In 2018, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) and managed by a global team across Europe and USA.

About CEVA:
Ceva Santé Animale is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Ceva’s mission summarised in the slogan, "Together, beyond animal health", This document is strictly confidential and not intended for circulation or publication, nor is it to be used, 2 or distributed without prior written consent of UNION therapeutics A/S. Violations may be legally prosecuted. recognises that the future health of animals, humans and our planet are inseparably bound together. Ceva is directly present in 45 countries around the world and have active business in over 110.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders today announced a partnership between Brown University, Rhode Island Hospital and UNION to join forces in the development of a new treatment for Helicobacter pylori. Morten Sommer, CSO at UNION, commented “We are honored and excited to be working with Professor Mylonakis and his group from Brown University to develop a new treatment with great prospects for patients across the world”

H. pylori is one of the world’s most prevalent pathogens and unless treated, colonization usually has lifelong persistence. Most people with H. pylori colonization never experience symptoms, however, each year millions colonized with H. pylori develop gastrointestinal diseases which are also linked to cancer and mortality. Unfortunately, the increase in antibiotic resistance is reducing effective treatment options, hence highlighting the need for new microbiome sparing alternatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced positive results from a Phase 1 Sensitization Study in 240 healthy adult volunteers with ATx201. The study was conducted in the US under IND as a randomized and placebo-controlled study. In comparing the active group to placebo, no signs of sensitization were observed, and no subjects showed any signs of unexpected adverse events.

Dr. Philippe Prokocimer, Chief Medical Officer of UNION commented: "The positive outcome of the sensitization study complements prior safety studies with ATx201, in both animals and humans. We are pleased that the studies support the safety and tolerability of ATx201 in both healthy and abraded skin".

Dr. Morten Sommer, the Chief Scientific Officer further added: “The safety and tolerability of ATx201 is of paramount importance given our focus on atopic dermatitis which is common in children. We express our genuine appreciation to the volunteers whose time and effort are helping the development of a much needed new treatment option”. ATx201 is currently being tested in atopic dermatitis patients, for which results are soon expected”.

UNION has previously completed two other Phase 1 studies with ATx201. One of them evaluated the ATx201 irritation potential in 36 healthy adult volunteers. All treatment regimens came out with positive results in both intact and abraded skin after daily applications for 21 days. The other Phase 1 study assessed the systemic safety, local tolerability of three dermal formulations of ATx201 in 30 healthy volunteers using a split-body design. The volunteers were treated twice daily with either ATx201 or placebo during a 7-day period. This study also demonstrated good safety as well as low systemic absorption of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements

Continue reading

Dr. Rasmus Toft-Kehler, Chief Executive Officer of AntibioTx, announced this week in Copenhagen that the company has officially changed its name to UNION therapeutics as of October 5, 2018.

”The new company name – UNION – reflects recent progress on the technology platform and expansion of expertise”, explained Dr. Toft-Kehler, and commented: “Our chemistry platform has provided compounds with very interesting immunological properties in combination with antimicrobial activity. The unique properties of our compounds will enable us to develop innovative treatments across a broad spectrum of diseases” and further adds “the expansion into immunology represents a new era for the company with great prospects for both patients and society”.

UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. UNION will initially focus on the treatment of inflammatory skin diseases, however, the chemistry platform and its versatile new modes of action is expected to be applicable across a wide range of diseases. The leadership team of UNION has invented and successfully developed more than 10 FDA-approved medicines. In 2017, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) with a US subsidiary and a global team.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutic A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced collaboration with Southern Illinois University in the search of new effective treatments against endometriosis. Dr. Rasmus Toft-Kehler CEO at AntibioTx commented “We are excited about the opportunity to collaborate with Dr. Kanako and her group to elucidate the potential for a novel treatment of endometriosis” to which Dr. Morten Sommer, CSO of AntibioTx further added “We have great confidence in the approach invented by Dr. Kanako and are committed to support this program with a clear aim to bring a new treatment to millions of patients with a very significant and neglected medical need”.

Endometriosis is a common long-term chronic disease that can have a profound impact on women’s physical health and quality of life. Symptoms typically appear when endometrial tissue is found outside the uterus causing significant pain and discomfort. Classic symptoms include intense pelvic pain, dysmenorrhea, dyspareunia and infertility. Malignant transformation of endometriosis may occur in up to 1% of women.  

Occurrence is mostly in women of childbearing age and most frequently in the age group 30-40 years. The prevalence is estimated to be 6-10% in the general female population, although the condition is considered to be underdiagnosed.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News